<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021541</url>
  </required_header>
  <id_info>
    <org_study_id>010222</org_study_id>
    <secondary_id>01-C-0222</secondary_id>
    <nct_id>NCT00021541</nct_id>
    <nct_alias>NCT00029354</nct_alias>
  </id_info>
  <brief_title>R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas</brief_title>
  <official_title>A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether the experimental drug R115777 (Tipifarnib) can shrink or slow
      the growth of plexiform neurofibromas in children and young adults with neurofibromatosis
      type 1 (NF1) and determine what side effects are related to treatment. Plexiform tumors arise
      from nerves; the only effective treatment is surgical removal. Often, however, not all the
      tumors can be removed, because of their number or location.

      Patients with NF1 have a reduced amount of the protein neurofibromin. Neurofibromin is
      thought to help control the activity of another protein, called ras, which regulates cell
      growth. Too little neurofibromin, therefore, may allow for uncontrolled cell growth and tumor
      formation. R115777 interferes with the function of the ras and other proteins. In test tube
      and animal studies, R115777 has blocked the growth of cancer cells. This study will examine
      whether the drug is effective against plexiform tumors.

      Patients with NF1 and progressive plexiform neurofibromas between 3 and 25 years of age may
      be eligible for this study. Patients whose tumors can be successfully removed surgically may
      not participate in this study. Candidates are screened with a medical history and physical
      and eye examinations, blood and urine tests, and magnetic resonance imaging (MRI).
      Photographs are taken of tumors visible on the body surface.

      Study participants are randomly assigned to receive either R115777 or placebo (an inactive
      substance). They take R115777 or placebo tablets every 12 hours for 21 days, followed by a
      7-day rest period. This constitutes one 28-day treatment cycle. Treatment continues for as
      long as the tumors remain stable or shrink and side effects are tolerable. The treatment is
      switched (for example, from placebo to R115777) or stopped if the tumors grow or if side
      effects become unacceptable. Patients (or their parents) keep a record of side effects.

      For the first 3 treatment cycles, patients have a physical examination and blood tests every
      other week. Blood tests are also done before starting treatment, and at one time point after
      at least 14 days of treatment to measure the effect of R115777 on proteins in blood cells. A
      blood sample is obtained before starting treatment and before cycles 4, 7 and 10 and then
      after every 6 cycles to measure the level of a substance called nerve growth factor. The
      analysis of nerve growth factor is used to determine if it can predict which patients might
      be at risk of developing side effects from R115777.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      R115777 (Tipifarnib) is a farnesyltransferase inhibitor that blocks the post-translational
      isoprenylation of ras and other farnesylated proteins. The ras proteins are integral in cell
      signaling pathways, and farnesylation is essential for the function of both mutant and
      non-mutant ras proteins. Patients with neurofibromatosis type 1 (NF1) have an increased risk
      of developing tumors of the central and peripheral nervous system, and there are no standard
      treatment options, other than surgery, available for these tumors. Neurofibromin, which is
      the product of the NF1 gene, contains a domain with significant homology to ras
      GTPase-activating proteins (GAP). Although NF1 patients lack germline ras mutations, the
      decreased levels of neurofibromin have been shown to be associated with a constitutively
      activated ras-GTP status. Thus, upstream inhibition of ras farnesylation may inhibit growth
      of tumors in NF1 patients. A randomized, cross-over, double-blinded, placebo-controlled
      pediatric phase II trial of oral R115777 will be performed in children and young adults with
      NF1, who have progressive, plexiform neurofibroma(s) to determine the effect of this novel
      anticancer drug on the rate of growth of neurofibromas. The endpoint of the trial is time to
      progression. R115777 will be administered orally at a dose of 200 mg/m(2) twice daily for
      cycles of 21 days followed by a 7 day rest period based on the results of our prior pediatric
      phase I trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2001</start_date>
  <completion_date type="Actual">February 19, 2009</completion_date>
  <primary_completion_date type="Actual">February 19, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Time to Progression</measure>
    <time_frame>8 years</time_frame>
    <description>Median time to progression is defined as a greater than or equal to 20% increase increase in the sum of the volume of all index lesions based on volumetric analysis utilizing magnetic resonance imaging (MRI).Start of phase A or phase B to time of progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>8 years</time_frame>
    <description>Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL)</measure>
    <time_frame>Baseline to pre cycle 4</time_frame>
    <description>Parents of participants aged 6-18 years completed the Impact of Pediatric Illness (IPI) Scale about their child prior to the start of cycles 1, 4, 7, and 10 and then after every 6 cycles. The IPI Scale assesses QOL in 4 domains: adaptive behavior, emotional functioning, medical/physical status, and cognitive functioning. Responses to the 43 items are made on a 5-point Likert scale (1-5) ranging from &quot;not al all&quot; to &quot;a lot&quot;. Higher mean scores indicate better QOL. Parent total scores for participants on placebo were compared with scores from participants receiving tipifarnib on phase A.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Median Time to Progression Using the Conventional 1-Dimensional Response Evaluation Criteria in Solid Tumors (RECIST) Method</measure>
    <time_frame>8 years</time_frame>
    <description>Median time to progression is defined as ≥20% increase in diameter based on volumetric analysis using the 1-dimensional RECIST method. Start of phase A or phase B to time of progression.</description>
  </other_outcome>
  <other_outcome>
    <measure>Median Time to Progression Using the 2-Dimensional World Health Organization (WHO) Solid Tumor Method</measure>
    <time_frame>8 years</time_frame>
    <description>Median time to progression is defined as ≥25% increase in area based on volumetric analysis using the 2-dimensional WHO solid tumor method.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Neurofibroma, Plexiform</condition>
  <condition>Neurofibromatosis Type I</condition>
  <arm_group>
    <arm_group_label>Tipifarnib (R11577)-Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral R115777 (Tipifarnib) first followed by placebo. 200 mg/m^2/dose BSA every 12 hours by mouth (po)on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo first followed by R115777 (Tipifarnib). 200 mg/m^2/dose BSA every 12 hours by mouth (po)every 12 hours on days 1-21. Courses repeat as in arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
    <description>Given orally, 200 mg/m^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days</description>
    <arm_group_label>Tipifarnib (R11577)-Arm I</arm_group_label>
    <other_name>R115777</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.</description>
    <arm_group_label>Placebo-Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Age: 3 years and 25 years of age.

        Diagnosis: Patients with neurofibromatosis type 1 (NF1) and progressive plexiform
        neurofibromas that have the potential to cause significant morbidity, such as (but not
        limited to) head and neck lesions that could compromise the airway or great vessels,
        brachial or lumbar plexus lesions that could cause nerve compression and loss of function,
        lesions that could result in major deformity (e.g., orbital lesions), lesions of the
        extremity that cause limb hypertrophy or loss of function, and painful lesions.

        Histologic confirmation of tumor is not necessary in the presence of consistent clinical
        and radiographic findings, clinically suspected.

        In addition to plexiform neurofibroma(s), all study subjects must have at least one other
        diagnostic criteria for NF1 listed below (National Institutes of Health (NIH) Consensus
        Conference[9]):

          1. Six or more cafe-au-lait spots (0.5 cm in prepubertal subjects or 1.5 cm in
             postpubertal subjects).

          2. Freckling in the axilla or groin;

          3. Optic glioma;

          4. Two or more Lisch nodules;

          5. A distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia or thinning of
             long bone cortex);

          6. A first degree relative with NF1.

        In this study a plexiform neurofibroma is defined as a neurofibroma that has grown along
        the length of a nerve and may involve multiple fascicles and branches.

        A spinal plexiform neurofibroma involves two or more levels with connection between the
        levels or extending laterally along the nerve.

        Measurable disease: Patients must have measurable plexiform neurofibroma(s). For the
        purpose of this study a measurable lesion will be defined as a lesion of at least 3 cm
        measured in one dimension.

        There must be evidence of recurrent or progressive disease as documented by an increase in
        size or the presence of new plexiform neurofibromas on MRI. Progression at the time of
        study entry is defined as:

          1. A measurable increase of the plexiform neurofibroma (20% increase in the volume, or a
             13% increase in the product of the two longest perpendicular diameters, or a 6%
             increase in the longest diameter) over the last two consecutive scans (magnetic
             resonance imaging (MRI) or computed tomography (CT)), or over the time period of
             approximately one year prior to evaluation for this study.

          2. Patients who underwent surgery for a progressive plexiform neurofibroma will be
             eligible to enter the study after the surgery, provided the plexiform neurofibroma was
             incompletely resected and is measurable.

             Prior therapy: Patients with NF1 are eligible at the time of recurrence or progression
             of inoperable plexiform neurofibroma.

             A surgical consultation should be obtained prior to enrollment on the study to
             evaluate if tumor resection is a feasible option.

             Patients will only be eligible if complete tumor resection is not feasible, or if a
             patient with surgical option refuses surgery.

             Since there is no standard effective chemotherapy for patients with NF1 and
             progressive plexiform neurofibromas, patients may be treated on this trial without
             having received prior therapy.

             Patients must have recovered from the toxic effects of all prior therapy before
             entering this study.

             The Cancer Therapy Evaluation Program Common Toxicity Criteria (CTC) Version 2.0 will
             be used for toxicity assessment.

             A copy of the CTC version 2.0 can be downloaded from the CTEP home page:
             http://ctep.cancer.gov. Recovery is defined as a toxicity grade less than 2, unless
             otherwise specified in the Inclusion and Exclusion Criteria.

             Patients must have had their last dose of radiation therapy at least six weeks prior
             to study entry, and their last dose of chemotherapy at least four weeks prior to study
             entry.

             Patients who received growth colony stimulating factor (G-CSF) after the prior cycle
             of chemotherapy must be off G-CSF for at least one week prior to entering this study.

             Performance Status: Patients should have a life expectancy of at least 12 months and
             an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1, or 2.

             Patients who are wheelchair bound because of paralysis should be considered
             'ambulatory' when they are up in their wheelchair.

             Hematologic Function: Patients must have an absolute granulocyte count 1,500/ uL, 9.0
             gm/dl, and a platelet count 150,000/uL at study entry, and a normal fibrinogen.

             Hepatic Function: Patients must have a bilirubin within normal limits and serum
             glutamic pyruvic transaminase (SGPT) 2x upper limit of normal.

             Patients with Gilbert syndrome are excluded from the requirement of a normal
             bilirubin. (Gilbert syndrome is found in 3-10% of the general population, and is
             characterized by mild, chronic unconjugated hyperbilirubinemia in the absence of liver
             disease or overt hemolysis).

             Renal Function: Patients must have an age-adjusted normal serum creatinine OR a
             creatinine clearance (70 mL / min / 1.73 m^2).

             Informed Consent: All patients or their legal guardians (if the patient is less than
             18 years old) must sign an institutional review board (IRB) approved document of
             informed consent (screening protocol) prior to performing studies obtained exclusively
             to determine patient eligibility.

             After confirmation of patient eligibility all patients or their legal guardians must
             sign the protocol specific informed consent to document their understanding of the
             investigational nature and the risk of this study before any protocol related studies
             are performed (other than the studies which were performed to determine patient
             eligibility).

             When appropriate pediatric patients will be included in all discussion. Per
             institutional guidelines, age appropriate assent forms for children from 7 through 12
             years, and for children may be developed and, when appropriate, will be signed by the
             pediatric patients in order to obtain written assent.

             Durable Power of Attorney (DPA):

             All patients 18 years of age will be offered the opportunity to assign DPA so that
             another person can make decisions about their medical care if they become
             incapacitated or cognitively impaired.

             Ability to undergo MRI examinations.

             EXCLUSION CRITERIA:

             Pregnant or breast feeding females are excluded, because the toxic effects and
             pharmacology of R115777 in the fetus and newborn are unknown.

             Clinically significant unrelated systemic illness (serious infections or significant
             cardiac, pulmonary, hepatic or other organ dysfunction) which in the judgement of the
             Principal or Associate Investigator would compromise the patient's ability to tolerate
             R115777 or are likely to interfere with the study procedures or results.

             Prior treatment with greater than 1 prior myelosuppressive chemotherapy regimen.

             An investigational agent within the past 30 days.

             Evidence of an optic glioma, malignant glioma, malignant peripheral nerve sheath tumor
             or other cancer requiring treatment with chemotherapy or radiation therapy.

             Ongoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor, or
             immunotherapy.

             Inability to return for follow-up visits or obtain follow-up studies required to
             assess toxicity and response to therapy.

             Prior treatment with R115777.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte Widemann, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Insitutes of Health, National Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (M1149)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles, CA (M1118)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital, Chicago, IL (M1484)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center (M1011)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital, Dana-Farber Cancer Institute, Boston, MA (M1034)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital, St. Louis, MO (M1123)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University, NY (M1303)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital (FWA 00002988)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Philadelphia, PA (M1257)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital, Houston, TX (M1060)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nord, Hamburg, Germany (FWA 00003228)</name>
      <address>
        <city>Hamburg</city>
        <zip>D-22419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bernards A. Neurofibromatosis type 1 and Ras-mediated signaling: filling in the GAPs. Biochim Biophys Acta. 1995 Jul 28;1242(1):43-59. Review.</citation>
    <PMID>7626654</PMID>
  </reference>
  <reference>
    <citation>De Santis S, Pace A, Bove L, Cognetti F, Properzi F, Fiore M, Triaca V, Savarese A, Simone MD, Jandolo B, Manzione L, Aloe L. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res. 2000 Jan;6(1):90-5.</citation>
    <PMID>10656436</PMID>
  </reference>
  <reference>
    <citation>Goldberg Y, Dibbern K, Klein J, Riccardi VM, Graham JM Jr. Neurofibromatosis type 1--an update and review for the primary pediatrician. Clin Pediatr (Phila). 1996 Nov;35(11):545-61. Review.</citation>
    <PMID>8953130</PMID>
  </reference>
  <results_reference>
    <citation>Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FM. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol. 2014 May;16(5):707-18. doi: 10.1093/neuonc/nou004. Epub 2014 Feb 4.</citation>
    <PMID>24500418</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 21, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2001</study_first_posted>
  <results_first_submitted>March 30, 2012</results_first_submitted>
  <results_first_submitted_qc>August 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 17, 2012</results_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Brigitte Widemann, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Surrogate Markers</keyword>
  <keyword>3-Dimensional Magnetic Resonance Imaging (MRI)</keyword>
  <keyword>Natural History of Neurofibromatosis Type 1 (NF1)</keyword>
  <keyword>Tumor Tissue Bank</keyword>
  <keyword>Neurofibromatosis</keyword>
  <keyword>NF1</keyword>
  <keyword>Neurofibromatosis Type 1</keyword>
  <keyword>Plexiform Neurofibroma</keyword>
  <keyword>Neurofibroma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurofibroma, Plexiform</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase A -Tipifarnib</title>
          <description>Patients receive oral tipifarnib every 12 hours on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Patients receive tipifarnib ONLY in the first treatment until they progress to the second treatment/crossover to receive placebo.</description>
        </group>
        <group group_id="P2">
          <title>Phase B - Placebo</title>
          <description>Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.Patients receive placebo ONLY in the first treatment until they progress to the second treatment/crossover to receive tipifarnib.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1-First Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31">These are the patients randomized to receive placebo. Two of these patients were deemed ineligible.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pts Who Progressed to Second Treatment</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ineligible Patients</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-adherence</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pts that did not progress</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2-crossover</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>refused phase B</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-adherence</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pts that did not progress</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase A-Tipifarnib</title>
          <description>Patients receive oral tipifarnib every 12 hours on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. These are the patients that started on tipifarnib only. This number does not reflect the total amount of patients that crossed over to placebo.</description>
        </group>
        <group group_id="B2">
          <title>Phase B - Placebo</title>
          <description>Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I. These are the patients that started on placebo only. This number does not reflect the total amount of patients that crossed over to tipifarnib. Two of the 31 patients were deemed ineligible, thus 29 started placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.2" spread="5.13"/>
                    <measurement group_id="B2" value="9.8" spread="4.69"/>
                    <measurement group_id="B3" value="10." spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Time to Progression</title>
        <description>Median time to progression is defined as a greater than or equal to 20% increase increase in the sum of the volume of all index lesions based on volumetric analysis utilizing magnetic resonance imaging (MRI).Start of phase A or phase B to time of progression.</description>
        <time_frame>8 years</time_frame>
        <population>phase A - 62 started and 2 were ineligible = 60 phase B - 43 started</population>
        <group_list>
          <group group_id="O1">
            <title>Phase A - Tipifarnib</title>
            <description>Tipifarnib</description>
          </group>
          <group group_id="O2">
            <title>Phase B - Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Progression</title>
          <description>Median time to progression is defined as a greater than or equal to 20% increase increase in the sum of the volume of all index lesions based on volumetric analysis utilizing magnetic resonance imaging (MRI).Start of phase A or phase B to time of progression.</description>
          <population>phase A - 62 started and 2 were ineligible = 60 phase B - 43 started</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="8.1" upper_limit="18.3"/>
                    <measurement group_id="O2" value="14.5" lower_limit="8.2" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tipifarnib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="8.1" upper_limit="30.3"/>
                    <measurement group_id="O2" value="13.3" lower_limit="8.0" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
        <time_frame>8 years</time_frame>
        <population>Adverse event data is in compliance with DSMB (Data Safety Monitoring Board).</population>
        <group_list>
          <group group_id="O1">
            <title>Tipifarnib &amp; Placebo</title>
            <description>Patients receive oral tipifarnib every 12 hours on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
          <population>Adverse event data is in compliance with DSMB (Data Safety Monitoring Board).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL)</title>
        <description>Parents of participants aged 6-18 years completed the Impact of Pediatric Illness (IPI) Scale about their child prior to the start of cycles 1, 4, 7, and 10 and then after every 6 cycles. The IPI Scale assesses QOL in 4 domains: adaptive behavior, emotional functioning, medical/physical status, and cognitive functioning. Responses to the 43 items are made on a 5-point Likert scale (1-5) ranging from &quot;not al all&quot; to &quot;a lot&quot;. Higher mean scores indicate better QOL. Parent total scores for participants on placebo were compared with scores from participants receiving tipifarnib on phase A.</description>
        <time_frame>Baseline to pre cycle 4</time_frame>
        <population>Participants analyzed includes only those whose parents completed the IPI Scale at baseline and pre cycle 4 on phase A.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase A - Tipifarnib</title>
            <description>Patients receive oral tipifarnib every 12 hours on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Phase B - Placebo</title>
            <description>Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QOL)</title>
          <description>Parents of participants aged 6-18 years completed the Impact of Pediatric Illness (IPI) Scale about their child prior to the start of cycles 1, 4, 7, and 10 and then after every 6 cycles. The IPI Scale assesses QOL in 4 domains: adaptive behavior, emotional functioning, medical/physical status, and cognitive functioning. Responses to the 43 items are made on a 5-point Likert scale (1-5) ranging from &quot;not al all&quot; to &quot;a lot&quot;. Higher mean scores indicate better QOL. Parent total scores for participants on placebo were compared with scores from participants receiving tipifarnib on phase A.</description>
          <population>Participants analyzed includes only those whose parents completed the IPI Scale at baseline and pre cycle 4 on phase A.</population>
          <units>Total scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="0.43"/>
                    <measurement group_id="O2" value="3.70" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre cycle 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="0.50"/>
                    <measurement group_id="O2" value="3.68" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Repeated measures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Post hoc test: tipifarnib group F=7.40</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Repeated measures ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Post hoc test: placebo group F=0.19</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Repeated measures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Time to Progression Using the Conventional 1-Dimensional Response Evaluation Criteria in Solid Tumors (RECIST) Method</title>
        <description>Median time to progression is defined as ≥20% increase in diameter based on volumetric analysis using the 1-dimensional RECIST method. Start of phase A or phase B to time of progression.</description>
        <time_frame>8 years</time_frame>
        <population>Phase B - Placebo group is not shown because this outcome measure only applies to the Phase A - Tipifarnib group.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase A - Tipifarnib</title>
            <description>Tipifarnib</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Progression Using the Conventional 1-Dimensional Response Evaluation Criteria in Solid Tumors (RECIST) Method</title>
          <description>Median time to progression is defined as ≥20% increase in diameter based on volumetric analysis using the 1-dimensional RECIST method. Start of phase A or phase B to time of progression.</description>
          <population>Phase B - Placebo group is not shown because this outcome measure only applies to the Phase A - Tipifarnib group.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">TTP was not reached because only one patient met criteria for progressive disease (e.g. insufficient number of participants to calculate TTP per protocol).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Time to Progression Using the 2-Dimensional World Health Organization (WHO) Solid Tumor Method</title>
        <description>Median time to progression is defined as ≥25% increase in area based on volumetric analysis using the 2-dimensional WHO solid tumor method.</description>
        <time_frame>8 years</time_frame>
        <population>Phase B- Placebo group is not shown because this outcome measure only applies to the Phase A - Tipifarnib group.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase A - Tipifarnib</title>
            <description>Tipifarnib</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Progression Using the 2-Dimensional World Health Organization (WHO) Solid Tumor Method</title>
          <description>Median time to progression is defined as ≥25% increase in area based on volumetric analysis using the 2-dimensional WHO solid tumor method.</description>
          <population>Phase B- Placebo group is not shown because this outcome measure only applies to the Phase A - Tipifarnib group.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" lower_limit="36.3" upper_limit="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 years</time_frame>
      <desc>Adverse event data is in compliance with DSMB(Data Safety Monitoring Board).</desc>
      <group_list>
        <group group_id="E1">
          <title>Tipifarnib &amp; Placebo</title>
          <description>Patients receive oral tipifarnib every 12 hours on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypofibrinogenemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fibrinogen</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="28" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mouth dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="30" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypofribrinogenemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Prolonged PT</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Prolonged PTT</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>white blood cell (WBC)</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bicarbonate</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain (neck)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain hands and feet</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neuropathy motor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neuropathy sensory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mood alteration-anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mood alteration-depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Personality/behavioral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Facial flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brigitte Widemann, M.D.</name_or_title>
      <organization>National Institutes of Health, National Cancer Institute</organization>
      <phone>301-496-7387</phone>
      <email>widemanb@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

